Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.08.27.672673

SMART: A Spatio-Molecular Atlas of Response Trajectories in Triple-Negative Breast Cancer

Abstract

A major challenge in treating Triple-Negative Breast Cancer (TNBC) lies in its molecular, morphological and clinical heterogeneity, which hampers accurate prediction of responses to neoadjuvant treatment. To address this, we introduce SMART: Spatio-Molecular Atlas of Response Trajectories, a comprehensive, multimodal resource compiled from 129 TNBC samples across 89 patients, obtained before, during, and after neoadjuvant chemotherapy (NACT). SMART comprises of 5,096 high quality manually selected spatial transcriptomic profiles enriched for epithelial, immune, or stromal compartments; paralleled with histological annotations, imagebased network analysis and protein expression. Seven novel spatial epithelial archetypes (EAs), seven tumour-immune microenvironments (TIMEs) and their co-localisation patterns were defined, revealing an opposing prevalence of functionally divergent EAs between response groups and the prognostic significance of B-cell enriched TIMEs, in particular those surrounding histologically normal epithelium adjacent to the tumour. The SMART dataset and analytical tools are publicly available via the PharosAI platform, providing the research community with the most comprehensive, manually annotated spatio-molecular transcriptomics atlas of NACT-treated TNBC to date.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Wall, I., Baptista, A., Parsons, M., Grigoriadis, A., Quist, J., Rafique, H., Verghese, G., Li, M., Marcotti, S., Phillips, T. A., Owczarek, C., Booker, G., Mera, A., Timbres, J., Sawyer, E., Gillet, C., Irshad, S., Pinder, S., Clausen, S., Tramm, T., King's Health Partners Biobank,, Ryan, L.. 2025-09-01. SMART: A Spatio-Molecular Atlas of Response Trajectories in Triple-Negative Breast Cancer. https://doi.org/10.1101/2025.08.27.672673

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

An expanded, phenotypically distinct tumor cell subset with low HPV mRNA increases recurrence risk

Human papillomavirus-related (HPV+) cancers harbor a subset of tumor cells expressing certain senescence-related transcripts and reduced levels of HPV mRNAs. We aimed to define this HPV-low population's biologic traits and clinical significance via integrated analysis of recurrence-prone human HPV+ oropharyngeal cancers (OPCs) and patient-derived xenografts (PDXs) of variable therapy sensitivity. Single-cell mRNA sequencing of PDXs and human tumors detected gene expression profiles in HPV-low cells indicating lack of senescence or terminal differentiation and intact tumorigenic capacity. HPV-low cells in cisplatin-refractory PDXs and particular human OPCs differentially upregulated multiple pathways linked to aggressive tumor biology, including RAS signaling, IL-6 signaling, and EMT. Predicted loss of cell-cell interactions among HPV-low cells reflected reduced epithelial identity, further supporting their more aggressive biology. Accordingly, the size of the pre-treatment HPV-low fraction had strong, independent association with recurrence risk. Genetic subclones within OPCs varied widely in content of HPV-low cells, which were enriched in particular lineages. Our findings uncover novel pro-tumor functions of HPV-low cells and support a central role for them in therapy resistance as well as potential utility as a clinical biomarker. Further elucidating mechanisms of cooperativity and plasticity between HPV-low and high states holds promise to reveal targets in treatment-refractory HPV+ malignancies.

cancer biology↗

Discovery of molecular glues for modulating MHC presentation of cancer neoantigens

Antigen presentation by MHC class I molecules is essential for cancer immunosurveillance, but many cancer-specific antigens fail to form complexes with Class I MHC and are poorly presented on the cell surface. In this study, we present a chemical strategy to overcome this limitation by identifying peptide MHC glues (PMGs) that promote the formation of peptide-MHC complexes with otherwise unpresentable cancer antigens. Crystal structures of these complexes show that our compounds stabilize antigen-MHC binding by making simultaneous interactions with the MHC protein and the antigen peptides. These findings reveal a new approach for chemically rewiring Class I MHC antigen presentation and accessing rare cancer antigens for therapeutic targeting.

cancer biology↗

mRNA-LNP vaccination induces microenvironment remodeling and generation of tissue-resident memory T cells in glioblastoma

Glioblastoma remains highly refractory to immunotherapy, in part because of a profoundly immunosuppressive tumour microenvironment that limits effective T-cell responses. Although mRNA vaccines can induce anti-tumour immunity, how they reshape the glioblastoma immune ecosystem to support durable tumour control is not well understood. Here we use an immunocompetent EGFRvIII-driven syngeneic glioblastoma model and antigen-specific mRNA lipid nanoparticle (mRNA-LNP) vaccination to define the cellular and spatial mechanisms underlying therapeutic response. In our model, vaccination induced durable EGFRvIII-specific humoral and cellular immunity, resulting in complete tumour eradication and long-term protection against intracranial rechallenge. Integrative analyses incorporating flow cytometry, tumour interstitial fluid profiling, multiplex immunostaining, spatial transcriptomics and ligand-receptor modelling demonstrated extensive remodelling of the tumour microenvironment following vaccination. Early tumour control was associated with expansion of pro-inflammatory and antigen-presenting myeloid populations, increased cytotoxic CD8 T-cell infiltration and activation, enhanced interferon-responsive signalling, and the formation of immune-supportive spatial niches enriched for antigen presentation and chemokine-mediated cellular communication. Vaccination promoted inflammatory chemokine relay networks centred on the CXCL16-CXCR6 axis, a pathway linked to tissue residency programming in the central nervous system. Functional depletion studies identified CD4 and CD8 T cells as essential mediators of therapeutic efficacy, while durable protection was maintained by tumour-specific brain-resident memory CD8 T cells that persisted despite peripheral lymphocyte depletion. Together, these findings identify T-cell-driven microenvironmental remodelling as a critical mechanism linking mRNA vaccination to the establishment of long-term brain-resident anti-tumour immunity in glioblastoma.

cancer biology↗